Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Sep 11, 2009

NEW YORK (GenomeWeb News) – 23andMe Co-founder Linda Avey has left the personal genomics services company to start a foundation that will focus on Alzheimer's disease. The foundation Avey will run will use the 23andMe research platform to search for causes of and treatments for the disease.

Avey's departure was effective as of Sept. 4, the day the announcement was made.

Avey and co-founder Anne Wojcicki started the company together around three years ago.


Mario Caccamo has been named head of bioinformatics for The Genome Analysis Centre in the UK. Caccamo worked until recently at the European Genome-Phenome Archive. The centre also recently appointed Amanda McMurray to be business development director.


DxS has appointed Patrik Dahlen to serve as a non-executive director. Dahlen formerly was CEO of cancer diagnostics firm Dako and CEO of BioImage, as well as president of life sciences and senior VP of PerkinElmer.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People in the News, a weekly roundup of industry comings and goings.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.